Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics.
Angiex has raised $31.0M in total funding. The most recent round was Undisclosed. The last funding was announced in November 2025.
Angiex's investors include Presight Capital, Thiel Capital, MassChallenge.
Angiex is headquartered in Cambridge, United States.
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics.
Angiex is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Angiex — Funding & Investors." VCBacked, November 14, 2025, https://www.vcbacked.co/company/angiex. Accessed October 30, 2026.
VCBacked. (2025). Angiex — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/angiex
{{cite web |title=Angiex — Funding & Investors |url=https://www.vcbacked.co/company/angiex |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated